Accumulating experimental evidence indicates that substantial activation of the PI3K/AKT signaling contributes to tumor cell resistance to conventional chemotherapy [44–47]. In glioblastomas, AKT activation can attenuate the therapeutic efficiency of temozolomide both in vitro and in vivo [25,28,48,49]. This evidence concerns the gene AKT1 and neoplasm.